Patient-Reported Outcomes with Olaparib plus Abiraterone Versus Placebo plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Phase 2 Trial – Beyond the Abstract
Prostate cancer, PROpel trial, homologous recombination repair mutation (HRRm), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Olaparib, Abiraterone, Olaparib plus Abiraterone Versus Placebo plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer, health-related quality of life (HRQoL), health-related quality of life results from PROpel trial.